Rapid response of stage IV colorectal cancer with APC/TP53/KRAS mutations to FOLFIRI and Bevacizumab combination chemotherapy: a case report of use of liquid biopsy
Abstract Background Liquid biopsies of blood plasma cell free DNA can be used to monitor treatment response and potentially detect mutations that are present in resistant clones in metastatic cancer patients. Case presentation In our non-interventional liquid biopsy study, a male patient in his fift...
Saved in:
Main Authors: | Alexander Hendricks (Author), Philip Rosenstiel (Author), Sebastian Hinz (Author), Greta Burmeister (Author), Christoph Röcken (Author), Kathrin Boersch (Author), Clemens Schafmayer (Author), Thomas Becker (Author), Andre Franke (Author), Michael Forster (Author) |
---|---|
Format: | Book |
Published: |
BMC,
2020-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Induction of pancreatic neoplasia in the KRAS/TP53 Oncopig
by: Pinaki Mondal, et al.
Published: (2023) -
Survival Prediction of Patients Treated With Immune Checkpoint Inhibitors via KRAS/TP53/EGFR-Single Gene Mutation
by: Shui Liu, et al.
Published: (2022) -
Case Report: Chemotherapy-free treatment with camrelizumab and anlotinib for elderly patients with KRAS and TP53 mutated advanced lung cancer
by: Wenbo Qi, et al.
Published: (2023) -
Regulation of IFN-γ-mediated PD-L1 expression by MYC in colorectal cancer with wild-type KRAS and TP53 and its clinical implications
by: Libin Guo, et al.
Published: (2022) -
Balanitis associated with FOLFIRI chemotherapy
by: Goran Micevic, PhD, et al.
Published: (2018)